PMID: 11910256Mar 23, 2002Paper

The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine

Journal of Clinical Psychopharmacology
Steven G PotkinLisa A Arvanitis

Abstract

The effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics and side-effect profile of quetiapine were investigated in 36 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a single-center, two-period, multiple-dose, open-label, randomized trial. Over a one-to two-week period, quetiapine doses were escalated to 300 mg twice daily (bid). Patients were then treated for at least 7 days at the target quetiapine dose and subsequently entered into the combination therapy period, receiving haloperidol (7.5 mg, bid), risperidone (3 mg, bid), or thioridazine (200 mg, bid) for 8.5 days (after 3 days of dose escalation). Key assessments included the pharmacokinetics of quetiapine at steady state (area under the curve within a dosing interval [AUCtSS], maximum [CmaxSS], and minimum [CminSS] observed plasma concentrations, and oral clearance [Cl/f]), as well as the UKU Side Effect Rating Scale scores and safety evaluations. Neither risperidone nor haloperidol had significant effects on quetiapine pharmacokinetics. However, thioridazine produced statistically significant changes, decreasing the least squares means values of the AUCtSS, CmaxSS, and CminSS by 40%, 47%, and 31%, respectively, and...Continue Reading

References

Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Apr 1, 1995·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·B L BlakeE Hodgson
Apr 1, 1996·Journal of Clinical Psychopharmacology·M J Byerly, C L DeVane
May 1, 1996·The British Journal of Psychiatry. Supplement·S R HirschL A Arvanitis
Apr 1, 1997·Cellular and Molecular Neurobiology·J FangR T Coutts
Nov 14, 1997·Acta Psychiatrica Scandinavica·J Peuskens, C G Link
Apr 1, 1998·CNS Drugs·N S Gunasekara, C M Spencer

❮ Previous
Next ❯

Citations

Dec 5, 2002·Pharmacoepidemiology and Drug Safety
Apr 23, 2013·Psychiatry Research·Taishiro KishimotoChristoph U Correll
Mar 26, 2002·Clinical Therapeutics·Andrew J CutlerJohn A Tumas
Jun 1, 2006·Neuropsychiatric Disease and Treatment·Emanuela MundoA Carlo Altamura
Apr 1, 2007·Neuropsychiatric Disease and Treatment·Michael RiedelHans-Jürgen Möller
Apr 24, 2012·CNS Drugs·Mark Sanford, Gillian M Keating
Feb 15, 2013·Pharmacological Reports : PR·Jacek WójcikowskiWładysława A Daniel
Feb 15, 2013·Pharmacological Reports : PR·Jacek WójcikowskiWładysława A Daniel
Jan 12, 2007·Basic & Clinical Pharmacology & Toxicology·Edoardo Spina, Jose de Leon
Jan 5, 2006·British Journal of Clinical Pharmacology·Scott W GrimmStots B Reele
Dec 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Prakash Masand
Jul 6, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ae-Ran ChoiSungpil Yoon
Jul 15, 2015·Journal of Analytical Toxicology·Louise SkovKristian Linnet
Oct 25, 2014·Journal of Analytical Toxicology·Louise SkovKristian Linnet
Sep 7, 2004·Journal of Clinical Psychopharmacology·Sebastian HärtterChristoph Hiemke
Nov 13, 2004·Journal of Clinical Psychopharmacology·Jose de LeonGeorge M Simpson
Nov 10, 2006·Journal of Psychopharmacology·Jenifer Chan, Melinda Sweeting
Sep 24, 2004·Therapeutic Drug Monitoring·Jørgen Hasselstrøm, Kristian Linnet
Dec 6, 2008·Journal of Psychiatric Practice·Anand K Pandurangi, Alican Dalkilic
Jul 26, 2005·Journal of Psychiatric Practice·Vijayalakshmy PatrickSteven Schleifer
Jul 21, 2006·The Cochrane Database of Systematic Reviews·A CiprianiJ R Geddes
Jul 18, 2006·Drug Metabolism and Drug Interactions·Jørgen Hasselstrøm, Kristian Linnet
Nov 15, 2012·Therapeutic Drug Monitoring·Lisbeth PatteetHugo Neels
Jun 23, 2011·Clinical Schizophrenia & Related Psychoses·Nancy Brahm, Christopher M Puls
May 10, 2007·Drugs·Gillian M Keating, Dean M Robinson
Oct 25, 2008·Joint Commission Journal on Quality and Patient Safety·Jessica L GörenRichard C Hermann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here